Neximmune

20 articles with Neximmune

• NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates

  3/31/2021

  NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its financial results for 2020 and highlighted recent corporate accomplishments

• NexImmune to Present at the 2021 Barclays Global Healthcare Conference

  3/2/2021

  NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.

• NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  2/17/2021

  NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response, today announced the closing of its previously announced upsized initial public offering of 7,441,650 shares of its common stock at a price to the public of $17.00 per share

• NexImmune Announces Pricing of Upsized Initial Public Offering

  2/11/2021

  NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share.

• 

  A Look at This Week’s Biotech IPOs

  1/22/2021

  The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look.
• 

  2021 Biotech IPOs Get Off to a Roaring Start

  1/20/2021

  Last year was a record number of IPOs in the biotech industry, with 81 raising $13.5 billion. With this kind of a start, 2021 may be scorching.

• NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor

  1/4/2021

  Both will help NexImmune advance current early-stage clinical trials and will guide Company’s translational efforts to develop new immunotherapy products

• Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition

  12/7/2020

  Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline

• NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting

  11/4/2020

  NexImmune announced that an abstract containing preliminary data from its first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia patients with relapsed disease has been selected for an oral presentation at the 62nd American Society of Hematology Annual Meeting to be held from December 5-8, 2020.

• NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia

  10/27/2020

  NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has signed a research initiative related to its AIM nanoparticle technology with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. City of Hope is a participating clinical site in the ongoing Phase 1/2 study of NEXI-001

• NexImmune Completes Dosing of First Cohort in Phase 1/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)

  9/23/2020

  Company is usi n g its Artificial Immune Modulation (AIM) nanoparticle technology to develop T cell immunotherapies for p atients with relapsed and/or refractory hematologic malignancies GAITHERSBURG, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique non-genetically-engineered T cell immunotherapies, announced today that it has completed dosing of the first safety cohort (n=3) in its Phase 1/2 clinical trial for NEXI-

• NexImmune to Present at the Jefferies Virtual Healthcare Conference

  6/1/2020

  NexImmune, a clinical-stage biopharma company advancing a new generation of nanoparticle-based therapies for targeted immune system response, today announced that John Trainer, Chief Financial Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 3:30 p.m. Eastern time. About NexImmune’s Lead T Cell Therapy Programs NexImmune’s two lead T cell therapy programs, NEXI-001 and N

• NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

  1/9/2020

  NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation nanotechnology platform, announced that industry veterans Han Myint, MD, and John Trainer, MBA, have been appointed as the Company’s Chief Medical Officer and Chief Financial Officer, respectively.

• NexImmune Appoints Sol Barer as Chairman of the Board of Directors

  12/16/2019

  NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation (AIM) nanotechnology platform, announced that Sol Barer, PhD has been appointed as the Company’s Chairman of the Board of Directors

• NexImmune Management to Present at Upcoming Conferences

  12/2/2019

  NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive Officer, will be particpating and presenting a corporate update at the following conferences

• NexImmune Receives IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

  10/31/2019

  NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, received Investigational New Drug (IND) clearance for the company’s first cellular therapy product

• 

  Celgene Co-Founder Bags $23M for Johns Hopkins Spinout NexImmune

  1/2/2018

  In conjunction with the financing, Tony Yao, MD, PhD, a Partner at ArrowMark Partners, will join NexImmune’s Board of Directors.

• Neximmune and the Leukemia & Lymphoma Society Enter Partnership for the Development of AIM ACT in AML Patients

  10/17/2017

  This will advance the Company’s novel cellular immunotherapy into Phase I clinical testing for patients with high risk AML who have relapsed after an allogeneic hematopoietic stem cell transplant.

• Novel Approach To Adoptive Immunotherapy Developed By Neximmune's Scientific Co-Founders

  7/15/2015

• Neximmune's AIM Immunotherapy Technology Enables Novel Adoptive Immunotherapy Approach For The Treatment Of Cancer

  2/25/2014